|
|
 |
|
Viewing report
|
|
|
|
Merck Serono S.A.: PharmaVitae Profile
Datamonitor, Dec 2007, Pages: 103
This analysis examines the historical and forecast performance for Merck-Serono in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Scope
Highlights of this title
Key reasons to purchase this title
- Benchmark Merck-Seronos performance against key rivals in the ethical pharmaceutical sector
- Learn how, led by Rebif and Erbitux, Merck-Serono is set to record strong growth relative to its peer set in the period to 2012
- Evaluate the prospects of Merck-Seronos late-stage pipeline, which is heavily dependent on the oral MS drug Mylinax
Customers who bought this item also bought
Merck Serono Biopharmaceuticals: PharmaVitae Profile
Partnering Agreements with Merck Serono 2010
Merck Serono S.A. - Strategic Analysis Review
Merck & Co. Inc: PharmaVitae Profile
Serono: PharmaVitae Profile
Merck Serono Partnering Guide 2008
Merck KGaA: PharmaVitae Model
Merck KGaA: Pipeline, Products, Performance and Potential
Merck & Co: Performance, Products, Pipeline and Potential
Merck Limited
Merck KGaA
Merck KGaA: PharmaVitae Profile 2005
|
|
|
|
